Quick answer
Extended answer
What are the most common research questions about Semaglutide?
Key facts
- Compound
- Semaglutide
- Class
- Long-acting GLP-1 receptor agonist
- Half-life
- ≈ 1 week (human, SC)
- Use
- In-vitro reference standard
Is Semaglutide a peptide?
Yes. Semaglutide is a 31-residue linear peptide with a lysine-26 fatty-di-acid modification. It is derived from the native incretin hormone GLP-1(7-37).
What receptor does Semaglutide target?
Semaglutide is a selective agonist of the glucagon-like peptide-1 receptor (GLP-1R), a class B G-protein-coupled receptor. It does not activate GIPR or GCGR at pharmacologically meaningful concentrations.
How is Semaglutide different from native GLP-1?
Semaglutide shares the core GLP-1(7-37) sequence with three key modifications: α-aminoisobutyric acid at position 8 (Aib8) to resist DPP-4 cleavage, arginine at position 34 (Arg34) to enable regioselective acylation, and a C18 fatty-di-acid attached at lysine-26 via a γGlu-2xOEG spacer that binds serum albumin.
Why does Semaglutide have such a long half-life?
The Aib8 substitution makes the peptide resistant to DPP-4, and the C18 fatty-di-acid side chain supports reversible non-covalent binding to serum albumin. Together these extend plasma half-life in humans to approximately one week.
What is the difference between Semaglutide and Tirzepatide?
Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide is a dual agonist engaging both the GLP-1 and GIP receptors from a single molecule. The two peptides share long-acting incretin pharmacology but differ in receptor coverage.
What is the difference between Semaglutide and Retatrutide?
Retatrutide is an investigational triple agonist engaging GLP-1R, GIPR and GCGR from a single molecule. Semaglutide is a selective GLP-1R agonist. Retatrutide's addition of GIP and glucagon receptor activity distinguishes it pharmacologically from Semaglutide.
What is the difference between Semaglutide and Liraglutide?
Both are acylated GLP-1 receptor agonists, but their acylation chemistry differs: Liraglutide carries a C16 mono-acid producing a ~13-hour half-life supporting once-daily dosing, while Semaglutide's C18 di-acid with a longer spacer supports a ~1-week half-life and once-weekly dosing.
Is oral Semaglutide the same molecule as injectable Semaglutide?
Yes. The active molecule in Rybelsus (oral) is identical to the active molecule in Ozempic and Wegovy (subcutaneous). The difference is formulation: oral Semaglutide is co-formulated with the absorption enhancer SNAC, which transiently raises local pH in the stomach and enables absorption of a small fraction of the dose.
What is SNAC and why is it used?
SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) is a small-molecule absorption enhancer used in oral Semaglutide. It transiently buffers local pH in the stomach, protecting the peptide from pepsin and increasing membrane permeability enough to allow absorption of a small but pharmacologically sufficient fraction of the dose.
Does Semaglutide activate the GIP or glucagon receptors?
No, not at pharmacologically meaningful concentrations. Semaglutide is a selective GLP-1R agonist. Dual (GLP-1R + GIPR) and triple (GLP-1R + GIPR + GCGR) agonism are features of separate compounds such as Tirzepatide and Retatrutide.
What is biased agonism at GLP-1R?
Biased agonism describes ligands that preferentially engage one branch of a receptor's signalling output — for example G-protein vs β-arrestin. GLP-1R exhibits both G-protein and arrestin signalling, and the therapeutic implications of ligand bias at this receptor are an active research area.
How should Semaglutide be reconstituted for laboratory research?
Reconstitute lyophilised Semaglutide by adding sterile or bacteriostatic water slowly against the vial wall, swirl gently — do not vortex — and allow complete dissolution. Aliquot into low-binding vials. See the Laboratory Reconstitution Guide for a full aseptic procedure.
How stable is reconstituted Semaglutide?
Reconstituted Semaglutide is generally used within days at 2–8 °C and stored longer-term as single-use aliquots at −20 °C. Freeze-thaw cycles should be minimised. Documented storage in low-binding vials protects against surface loss driven by the acylated side chain.
What analytical methods confirm Semaglutide identity?
Reversed-phase HPLC at 214 nm is the standard purity method (target ≥ 98% area). LC-MS confirms identity against the theoretical mass (≈ 4113.58 g/mol average). SEC-HPLC is useful for monitoring aggregation of the acylated peptide.
What preclinical models are used for Semaglutide research?
Common models include cell-based cAMP and β-arrestin assays on GLP-1R-expressing cell lines, isolated pancreatic islet insulin-secretion studies, rodent diet-induced obesity models and central neuroanatomical studies mapping distributed brainstem and hypothalamic engagement.
What was the SELECT trial?
SELECT was a randomised placebo-controlled cardiovascular outcomes trial of subcutaneous Semaglutide in adults with overweight or obesity and pre-existing cardiovascular disease but without diabetes (Lincoff et al., 2023). It reported a significant reduction in major adverse cardiovascular events (MACE) versus placebo.
What was the STEP program?
STEP is a family of randomised trials evaluating subcutaneous Semaglutide (2.4 mg once weekly) for weight management. STEP-1 (Wilding et al., 2021) reported substantial mean weight reduction versus placebo in adults with overweight or obesity.
Why do GLP-1 agonists reduce appetite?
GLP-1 receptors are expressed on vagal afferents and multiple central nervous system populations relevant to appetite regulation, including brainstem NTS and hypothalamic POMC and NPY neurons. GLP-1R agonism engages these circuits, and rodent work with Semaglutide demonstrates distributed neural engagement consistent with reduced food intake.
What are the known limitations of Semaglutide preclinical evidence?
In-vitro potency for acylated GLP-1 analogues is sensitive to buffer albumin and plasticware. Central mechanism data derive mainly from rodent models. Long-term (>5 year) real-world data continue to accumulate, and off-label investigational uses rest on smaller data sets than metabolic and cardiovascular endpoints.
Is Semaglutide safe for human use?
Approved Semaglutide medicines (Ozempic, Wegovy, Rybelsus) are regulated by the MHRA in the United Kingdom and are prescribed by qualified clinicians who assess indication, contraindication and risk. Oxford Research Peptides does not supply approved medicines and Semaglutide reference standards from Oxford Research Peptides are intended solely for in-vitro laboratory research.
For deeper reading see the Semaglutide monograph, What is Semaglutide?, Mechanism of Action guide, GLP-1 receptor explained, Triple agonists explained and the Retatrutide monograph. Related glossary anchors: GLP-1, incretin, incretin effect, biased agonism, β-arrestin, acylation and albumin binding.
Evidence summary
- What is Semaglutide?
Beginner-friendly research-focused introduction to Semaglutide — a long-acting GLP-1 receptor agonist derived from native GLP-1(7-37).
- Semaglutide Mechanism of Action
Receptor-level explanation of Semaglutide's activity at GLP-1R — Gαs / cAMP / PKA / EPAC2 signalling, β-arrestin recruitment, insulinotropic and glucagonostatic effects, gastric emptying and central appetite modulation.
- Semaglutide FAQ
Comprehensive research-focused FAQ on Semaglutide — identity, receptor pharmacology, structural modifications, pharmacokinetics, laboratory handling, evidence base and regulatory status.
- Semaglutide Pharmacokinetics
Reported pharmacokinetics of Semaglutide — half-life, albumin binding, C18 di-acid acylation, absorption for subcutaneous vs oral formulations, distribution, steady state and research limitations.
- Semaglutide Research Applications
Overview of published Semaglutide research contexts — metabolic, cardiovascular, renal, neuroinflammation/CNS and NAFLD/MASH — with a clear preclinical vs human evidence split.
- Albumin Binding and Half-Life Extension
Reusable mechanism guide explaining how fatty-acid acylation supports reversible non-covalent binding to serum albumin, and how that extends the plasma half-life of GLP-1 peptides.
Research use only
Publication information
- Published
- 2026-09-02
- Updated
- 2026-09-02
- Reviewed
- 2026-09-02
- Version
- 1.0
Revision history
- v1.02026-09-02· Editorial Team
Initial publication of the Semaglutide cornerstone cluster (Authority Sprint 2B, Wave 1).
Editorial standards
Content is reviewed against our editorial process for scientific accuracy, sourcing, and clarity. Read our editorial standards.
Conflict of interest
Next scheduled review: 2028-03-02. Our research methodology describes how the review is conducted.